Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

This study has been completed.
Sponsor:
Information provided by:
MEDA Pharma GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT00328601
First received: May 19, 2006
Last updated: July 29, 2008
Last verified: July 2008
  Purpose

The primary objective of the trial is to determine the optimal dose of orally (tablet) administered thioctic acid in the treatment of symptoms of diabetic polyneuropathy (dPNP). It is expected that at least one of the three dosages to be tested (600, 1200, or 1800 mg tablets) of orally administered thioctic acid improves the symptoms of dPNP as compared to placebo.

Secondary objectives are evaluations of other variables pertinent to dPNP, safety, and tolerability.


Condition Intervention Phase
Diabetic Polyneuropathy
Drug: Thioctic Acid
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups

Resource links provided by NLM:


Further study details as provided by MEDA Pharma GmbH & Co. KG:

Estimated Enrollment: 170
Study Start Date: February 2005
Estimated Study Completion Date: June 2005
Detailed Description:

Following a screening visit, patients will receive placebo oral for 7 days. Eligible patients with chronic symptoms will then randomly be assigned to one of 4 treatment groups and treated with trial medication for 5 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diabetes mellitus (Type I or II), as defined by the American Diabetes Association, 1997, lasting 1 year.
  2. Patient must have a symmetric sensory-motor peripheral polyneuropathy of at least stage 2 attributable to diabetes mellitus following a thorough evaluation for other causes of neuropathy.
  3. HbA1C < 10%.
  4. TSS > 7.5 points.
  5. NISLL > 2 points.
  6. Pain sensation (according to pin-prick sensitivity test) absent or decreased (NIS item 35 1).
  7. Age range: 18 to 74 years. Inclusion criteria prior to randomisation
  8. The TSS must be > 5 points
  9. The TSS range (maximum TSS minus minimum TSS during the run-in phase) must be less than 3 points to avoid inclusion of patients with rapidly oscillating symptoms.
  10. At least 1 of the 4 symptoms of the TSS must have occurred continuously over the last 3 months.
  11. Lack of compliance, i.e. below 85% or above 115% (Accordingly, 6 daily doses taken of the 7 daily doses scheduled for Phase A would be acceptable).

Exclusion Criteria:

Lack of suitability for the trial:

  1. Proximal asymmetric neuropathy, cranial neuropathies, truncal radiculopathy, diabetic plexopathies, or acute or active mononeuropathies (including cranial neuropathies, post-herpes neuralgias, etc.), with the exception of carpal tunnel syndrome (CTS) or tardy ulnar neuropathy (TUN) or both.
  2. Neuropathy of any cause other than diabetes mellitus which might interfere with the assessment of the severity of dPNP.
  3. Other neurologic diseases that may produce weakness, sensory loss, or autonomic symptoms or test abnormality.
  4. Myopathy of any cause.
  5. Peripheral vascular disease severe enough to cause intermittent claudication or ischemic ulcers or limb ischemia.
  6. Patients with proliferating retinopathy requiring immediately therapy and impending blindness.
  7. Psychiatric, psychological, or behavioural symptoms that would interfere with the patient's ability to participate in the trial.
  8. Patients with any active neoplastic disease except basal cell carcinoma.
  9. Patients with atrial fibrillation unless controlled and stabilised by medication.
  10. Patients with clinically significant cardiac, pulmonary, gastrointestinal, haematological, or endocrine disease (other than diabetes) that may confound interpretation of the study results or prevent the patient from completing the study.
  11. Patients who have had organ transplants of any kind.
  12. Patients with significant hepatic or renal disease (ASAT, ALAT or GGT >2 times normal, serum creatinine >1.8 mg/dL (>159 mmol/l) for males or >1.6 mg/dL (>141 mmol/l) for females).
  13. Patients with a recent history (within last 12 months) of drug or alcohol abuse.
  14. Use of any investigational drug (participation in a clinical trial) within last 1 month.
  15. History of severe or anaphylactic reaction to drugs, sulfur or biologic products.
  16. Recent (within last 3 months) ketoacidosis or hypoglycaemia, necessitating hospital admission.
  17. Antioxidant therapy (vitamins E > 400 IU, C > 200 mg, and beta-Carotene > 30 mg) or pentoxyphylline within last 1 month before start of trial.
  18. Use of thioctic acid (> 50 mg), evening primrose oil or any other gamma-linolenic acid containing substance within the last 3 months.
  19. Continued use of medications listed in section 6.2.3.
  20. Bilateral sural nerve biopsies.
  21. Existing foot ulcers.

    Safety concerns:

  22. Pregnant or lactating females: Pregnancy as evidenced by positive b-hCG-test at screening visit or by testing performed at the study site on demand, or women of child-bearing potential not using adequate contraception.
  23. History of allergic reaction to the study medication or its excipients.

    Administrative reasons:

  24. Informed Consent is not signed or the patient has not complete competence to co-operate.
  25. Any language barriers that can affect adequate understanding.
  26. Anticipated non-availability for study visits/procedures.
  27. Vulnerable subjects (such as persons kept in detention)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00328601

Locations
Israel
Wolfson Medical Center, Diabetes Unit
Holon, Israel, 58100
Haddassah Medical Center Ein Kerem, Diabetes Unit
Jerusalem, Israel, 91120
Russian Federation
Chair of Endocrinology and Diabetology of Russian Medical Academy of Postgraduate Education at Central Clinical Hospital of Ministry of Communication RF
Moscow, Russian Federation, 125315
Chair of Nervous Diseases of IM Sechenov Moscow Medical Academy at City Clinical Hospital
Moscow, Russian Federation, 119048
Federal Centre of Medical Social Expertise and Rehabilitation of Invalids, Centre Diabetic Food
Moscow, Russian Federation, 127486
Sponsors and Collaborators
MEDA Pharma GmbH & Co. KG
Investigators
Principal Investigator: Dan Ziegler, Prof. German Diabetes Research Institute, Heinrich Heine University, Auf'm Hennekamp 65, D-40225 Düsseldorf, Germany
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00328601     History of Changes
Other Study ID Numbers: D-20557-3258
Study First Received: May 19, 2006
Last Updated: July 29, 2008
Health Authority: Russia: Ethics Committee
Israel: Ethics Commission

Additional relevant MeSH terms:
Diabetic Neuropathies
Polyneuropathies
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Diseases
Thioctic Acid
Antioxidants
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Vitamin B Complex
Vitamins

ClinicalTrials.gov processed this record on November 24, 2014